Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 5/20 | 0.41 |
| ▸ | HTR2C | P28335 | 5/20 | 0.41 |
| ▸ | HTR2B | P41595 | 4/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.39 |
| ▸ | PRKCG | P05129 | 1/20 | 0.38 |
| ▸ | PRKCA | P17252 | 1/20 | 0.38 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21172504 | 1.00 | NOTUM (0.43) | NOTUMHTR2AHTR2CHTR2BADRA2A | |
| SCHEMBL21172724 | 1.00 | NOTUM (0.43) | NOTUMHTR2AHTR2CHTR2BADRA2A | |
| SCHEMBL12340979 | 0.89 | NOTUM (0.41) | NOTUMHTR2AHTR2CHTR2BADRA2A | |
| SCHEMBL21172695 | 0.81 | NOTUM (0.41) | NOTUMHTR2AHTR2CHTR2BADRA2A | |
| SCHEMBL7733992 | 0.79 | NOTUM (0.55) | NOTUMHTR2AHTR2CHTR2BADRA2A | |
| SCHEMBL6890897 | 0.79 | NOTUM (0.55) | NOTUMHTR2AHTR2CHTR2BADRA2A | |
| SCHEMBL31672940 | 0.79 | NOTUM (0.55) | NOTUMHTR2AHTR2CHTR2BADRA2A | |
| SCHEMBL811795 | 0.79 | NOTUM (0.55) | NOTUMHTR2AHTR2CHTR2BADRA2A | |
| SCHEMBL28217680 | 0.78 | HTR2A (0.44) | NOTUMHTR2AHTR2CHTR2BADRA2A | |
| SCHEMBL28217735 | 0.78 | NOTUM (0.42) | NOTUMHTR2AHTR2CHTR2BADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0495250-B1 | Cationic 1,3,4 thiadiazole dyes | BAYER AG (DE) | 1996-01-31 | — | — | EP | claimed |
| EP-0495250-A1 | Cationic 1,3,4 thiadiazole dyes | BAYER AG (DE) | 1992-07-22 | — | — | EP | claimed |
| US-9748044-B2 | Photosensitizer and photoelectric conversion device | CHEMICREA INC. (JP) | 2017-08-29 | — | — | US | disclosed |
| US-9703128-B2 | Method for making an integrated circuit having optical data communication | BrPhotonics Produtos Optoeletronicos LTDA (BR) | 2017-07-11 | — | — | US | disclosed |
| EP-3152306-A1 | METHODS AND COMPOUNDS FOR PHOTOTHERAPY WITH CHALCOGENORHODAMINE PHOTOSENSITIZERS | Wake Forest University Health Sciences, Inc. (US) | 2017-04-12 | — | — | EP | disclosed |
| US-20170096636-A1 | METHODS AND COMPOUNDS FOR PHOTOTHERAPY WITH CHALCOGENORHODAMINE PHOTOSENSITIZERS | UNIV WAKE FOREST HEALTH SCIENCES (US) | 2017-04-06 | — | — | US | disclosed |
| US-20170092436-A1 | PHOTOSENSITIZER AND PHOTOELECTRIC CONVERSION DEVICE | CHEMICREA INC. (JP) | 2017-03-30 | — | — | US | disclosed |
| US-20160349547-A1 | METHOD FOR MAKING AN INTEGRATED CIRCUIT HAVING OPTICAL DATA COMMUNICATION | LIGHTWAVE LOGIC, INC. | 2016-12-01 | — | — | US | disclosed |
| WO-2015187940-A1 | METHODS AND COMPOUNDS FOR PHOTOTHERAPY WITH CHALCOGENORHODAMINE PHOTOSENSITIZERS | WAKE FOREST UNIVERSITY HEALTH SCIENCES (US) | 2015-12-10 | — | — | WO | disclosed |
| US-8934741-B2 | Integrated circuit with optical data communication | Brphotonics Produtos Optoelectronicos LTDA (BR) | 2015-01-13 | — | — | US | disclosed |
| US-20140302250-A1 | ELECTRO-OPTIC POLYMER AND ELECTRO-OPTIC DEVICES MADE THEREFROM | GIGOPTIX, INC. (US) | 2014-10-09 | — | — | US | disclosed |
| WO-2012037377-A2 | INTEGRATED CIRCUIT WITH OPTICAL DATA COMMUNICATION | GIGOPTIX, INC. (US) | 2012-03-22 | — | — | WO | disclosed |
| US-20110118232-A1 | PYRIMIDINE COMPOUNDS AND USE THEREOF | ABBOTT GMBH & CO. KG (DE) | 2011-05-19 | — | — | US | disclosed |
| US-7786105-B2 | Pyrimidine compounds and use thereof | ABBOTT GMBH & CO. KG (DE) | 2010-08-31 | — | — | US | disclosed |
| US-20090111807-A1 | Novel 1,2,3,4-Tetrahydroquinoxaline Derivative Having Glucocorticoid Receptor Binding Activity | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2009-04-30 | — | — | US | disclosed |
| US-20080161322-A1 | e.g. 1-[2-tert-Butyl-6-(trifluoromethyl)pyrimidin-4-yl]-4-[3-(2-oxo-3,4-dihydroquinolin-1(2H)-yl)propyl]piperazin-4-ium chloride3,4-Dihydroquinolin-2(1H)-one; dopamine D3 receptor antagonists or agonists; antidepressant, schizophrenia, Parkinson's disease | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2008-07-03 | — | — | US | disclosed |
| EP-0495250-B1 | Cationic 1,3,4 thiadiazole dyes | BAYER AG (DE) | 1996-01-31 | — | — | EP | disclosed |
| US-5208325-A | CATIONIC 1,3,4-THIADIAZOLE DYESTUFFS | BAYER AKTIENGESELLSCHAFT (DE) | 1993-05-04 | — | — | US | disclosed |
| EP-0495250-A1 | Cationic 1,3,4 thiadiazole dyes | BAYER AG (DE) | 1992-07-22 | — | — | EP | disclosed |
| US-3991042-A | Basic azo dyestuffs containing a benzthiazole and a tetrahydroquinoline nucleus | BAYER AKTIENGESELLSCHAFT (DT) | 1976-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161322-A1 | e.g. 1-[2-tert-Butyl-6-(trifluoromethyl)pyrimidin-4-yl]-4-[3-(2-oxo-3,4-dihydroquinolin-1(2H)-yl)propyl]piperazin-4-ium chloride3,4-Dihydroquinolin-2(1H)-one; dopamine D3 receptor antagonists or agonists; antidepressant, schizophrenia, Parkinson's disease | SLC6A3, GRM3, GPR3 | NOTUM 4561/4885HTR2A 109/4885HTR2C 49/4885 |
| US-20170096636-A1 | METHODS AND COMPOUNDS FOR PHOTOTHERAPY WITH CHALCOGENORHODAMINE PHOTOSENSITIZERS | CD4, CD74, NFATC1 | NOTUM 2043/4885HTR2A 3808/4885HTR2C 4021/4885 |
| US-20110118232-A1 | PYRIMIDINE COMPOUNDS AND USE THEREOF | CRHR1, CRHR2, MC2R | NOTUM 4351/4885HTR2A 339/4885HTR2C 177/4885 |
| US-20090111807-A1 | Novel 1,2,3,4-Tetrahydroquinoxaline Derivative Having Glucocorticoid Receptor Binding Activity | NR3C1, NR3C2, MC2R | NOTUM 1649/4885HTR2A 568/4885HTR2C 534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.